


CDC Clinical Guidance for 2nd Booster Dose

Elisha Hall, PhD, RD
Clinical Guidelines Lead



Advisory Committee on Immunization Practices Meeting
4/20/2022



cdc.gov/coronavirus

2nd Booster Doses


- Some populations **may** receive a second booster dose using an mRNA COVID-19 vaccine **at least 4 months** after the first booster dose



People ages 50 years
and older



People ages 12 years
and older who are
moderately or severely
immunocompromised



People ages 18 years
and older who received
Janssen as both
primary and booster
dose

2nd Booster Dose Product

- 2nd booster dose should be an mRNA COVID-19 vaccine (i.e., Pfizer-BioNTech or Moderna).
- Janssen COVID-19 Vaccine is not authorized for use as a second booster.
- Booster doses may be heterologous.
 - Eligible people ages 12–17 years can only receive Pfizer-BioNTech COVID-19 Vaccine.
- The dosage is the same as the first booster dose
 - Pfizer-BioNTech (gray or purple cap): 0.3 mL (30 mcg)
 - Moderna (red cap): 0.25 mL (50 mcg)

Emergency Use Authorization and Emergency Use Instructions

EUA¹

- People ages 50 years and older
- People ages 12 years and older who are moderately or severely immunocompromised

EUI²

- People ages 18 years and older who received Janssen as both primary and booster dose

¹<https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/covid-19-vaccines>

²<https://www.cdc.gov/vaccines/covid-19/eui/index.html>

Emergency Use Instructions (EUI)

The screenshot shows the CDC website page for COVID-19 Vaccine Emergency Use Instructions (EUI). The page is titled "COVID-19 Vaccine Emergency Use Instructions (EUI) Resources" and is part of the "Vaccines & Immunizations" section. The breadcrumb trail is "CDC > COVID-19 Vaccination > Product Info by U.S. Vaccine". The left sidebar lists various categories, with "EUI" selected. The main content area includes a paragraph explaining that the CDC issued initial EUI for the Pfizer-BioNTech COVID-19 vaccine on November 17, 2021, and another EUI for the Moderna COVID-19 vaccine on February 11, 2022. Below this, there are two columns of resources: "For Healthcare Providers" and "For Recipients and Caregivers". The "For Healthcare Providers" column lists "Pfizer-BioNTech Vaccine EUI Fact Sheet" and "Moderna Vaccine EUI Fact Sheet". The "For Recipients and Caregivers" column lists "Pfizer-BioNTech Vaccine EUI Fact Sheet" and "Moderna Vaccine EUI Fact Sheet", each with links for "English" and "Spanish". At the bottom, there is a section for "EUI FAQs" with the text "Find answers to your questions about EUI".

Vaccines & Immunizations

CDC > COVID-19 Vaccination > Product Info by U.S. Vaccine

COVID-19 Vaccination

Product Info by U.S. Vaccine

- Pfizer-BioNTech Vaccines
- Moderna Vaccine
- Janssen/J&J Vaccine
- EUA
- EUI**
- FAQs for Healthcare Professionals
- Interim Clinical Considerations
- Clinical Care
- Provider Requirements and Support
- Training and Education
- Vaccine Recipient Education

COVID-19 Vaccine Emergency Use Instructions (EUI) Resources

CDC issued initial Emergency Use Instructions (EUI) for the Pfizer-BioNTech COVID-19 vaccine on November 17, 2021, and another EUI for the Moderna COVID-19 vaccine on February 11, 2022. EUI provide information about emergency use of FDA-approved medical products that may not be included in or differ in some way from the information provided in the FDA-approved labeling (package insert). See below the CDC-issued EUI fact sheets for healthcare providers and recipients/caregivers regarding Pfizer-BioNTech COVID-19 vaccine, Moderna COVID-19 vaccine, and FAQs.

For Healthcare Providers

- Pfizer-BioNTech Vaccine EUI Fact Sheet
- Moderna Vaccine EUI Fact Sheet

For Recipients and Caregivers

- Pfizer-BioNTech Vaccine EUI Fact Sheet
English | Spanish
- Moderna Vaccine EUI Fact Sheet
English | Spanish

EUI FAQs

Find answers to your questions about EUI


<https://www.cdc.gov/vaccines/covid-19/eui/index.html>


Up to Date

- CDC recommends everyone get up to date with their COVID-19 vaccinations.
- Being up to date means a person has received all recommended doses in their primary vaccine series, and a booster dose, when eligible.
- Receipt of a second booster dose is not necessary to be considered up to date at this time.


<https://www.cdc.gov/coronavirus/2019-ncov/vaccines/stay-up-to-date.html>

Summary of Recommendations by Primary Series Product and Age

 Everyone in the age group **SHOULD** receive the dose

 Some people in the age group **MAY** receive the dose


Pfizer-BioNTech
(ages 5-11 years)




Pfizer-BioNTech
(ages 12 years and older)



Moderna
(ages 18 years and older)





Janssen (J&J)
(ages 18 years and older)




People ages 50 years and older

Summary of Recommendations by Primary Series Product and Age

 **Everyone** in the age group **SHOULD** receive the dose

 **Some people** in the age group **MAY** receive the dose

Pfizer-BioNTech
(ages 5-11 years)



Pfizer-BioNTech
(ages 12 years and older)



Moderna
(ages 18 years and older)



Janssen (J&J)
(ages 18 years and older)



People ages 50 years and older

People ages 18 years and older who received 2 Janssen doses

Summary of Recommendations by Primary Series Product and Age




Everyone in the age group **SHOULD** receive the dose




Some people in the age group **MAY** receive the dose


Pfizer-BioNTech
(ages 5-11 years)



Pfizer-BioNTech
(ages 12 years and older)



Moderna
(ages 18 years and older)





Janssen (J&J)
(ages 18 years and older)




People ages 50 years and older

Summary of Recommendations by Primary Series Product and Age

 **Everyone** in the age group **SHOULD** receive the dose

 **Some people** in the age group **MAY** receive the dose

Pfizer-BioNTech
(ages 5-11 years)




Pfizer-BioNTech
(ages 12 years and older)



Moderna
(ages 18 years and older)



Janssen (J&J)
(ages 18 years and older)



People ages 50 years and older

Summary of Recommendations by Primary Series Product and Age, Moderately or Severely Immunocompromised



Everyone in the age group **SHOULD** receive the dose



Some people in the age group **MAY** receive the dose


Pfizer-BioNTech
(ages 5–11 years)




Pfizer-BioNTech
(ages 12 years and older)



Moderna
(ages 18 years and older)



Janssen (J&J)
(ages 18 years and older)



Summary of Recommendations by Primary Series Product and Age, Moderately or Severely Immunocompromised




Everyone in the age group **SHOULD** receive the dose



Some people in the age group **MAY** receive the dose

Pfizer-BioNTech
(ages 5–11 years)




Pfizer-BioNTech
(ages 12 years and older)



Moderna
(ages 18 years and older)



Janssen (J&J)
(ages 18 years and older)



Summary of Recommendations by Primary Series Product and Age, Moderately or Severely Immunocompromised



Everyone in the age group **SHOULD** receive the dose




Some people in the age group **MAY** receive the dose


Pfizer-BioNTech
(ages 5–11 years)




Pfizer-BioNTech
(ages 12 years and older)



Moderna
(ages 18 years and older)



Janssen (J&J)
(ages 18 years and older)



Summary of Recommendations by Primary Series Product and Age, Moderately or Severely Immunocompromised



Everyone in the age group **SHOULD** receive the dose




Some people in the age group **MAY** receive the dose


Pfizer-BioNTech
(ages 5–11 years)




Pfizer-BioNTech
(ages 12 years and older)








Moderna
(ages 18 years and older)





Janssen (J&J)
(ages 18 years and older)



Eligible People Who May Consider Getting the 2nd Booster Dose As Soon As Possible

-  People with certain underlying medical conditions that increase the risk of severe COVID-19 illness
-  People who are moderately or severely immunocompromised
-  People who live with someone who is immunocompromised, at increased risk for severe disease, or who cannot be vaccinated due to age or contraindication
-  People at increased risk of exposure to SARS-CoV-2, such as through occupational, institutional, or other activities (e.g., travel or large gatherings)
-  People living or working in an area where the COVID-19 community level is medium or high

Eligible People Who May Consider Waiting to Receive a 2nd Booster Dose

-  People with recent SARS-CoV-2 infection within the past 3 months
-  People who may be hesitant about getting another recommended booster dose in the future, as a booster dose may be more important in the fall and/or if a variant-specific vaccine is needed.





Education and Communication



Clinical Considerations Second COVID-19 Vaccine Booster Dose

Everyone ages 12 years and older **should** get a booster when they are eligible. Some people **may** get a 2nd booster dose.

When you discuss a 2nd COVID-19 vaccine booster dose with patients:

Who is eligible: 	<ul style="list-style-type: none"> People 50 years of age and older, regardless of health status People 12 years of age and older who are moderately or severely immunocompromised People 18 years of age and older and received 2 doses of Janssen vaccine
Who might consider getting the 2nd booster dose now: 	<ul style="list-style-type: none"> People with underlying medical conditions that increase the risk of severe COVID-19 disease People who are moderately or severely immunocompromised People who live with someone who is immunocompromised, at increased risk for severe disease, or who cannot be vaccinated due to age or contraindication People at increased risk of exposure to SARS-CoV-2, such as through occupational, institutional, or other activities (e.g., travel or large gatherings) People living or working in an area where there is increased concern about COVID-19 community levels
Who might consider waiting to receive a 2nd booster dose: 	<ul style="list-style-type: none"> People with recent (within the past 3 months) SARS-CoV-2 infection People who may have reservations about getting another recommended booster dose in the future; a booster dose may be more important in the fall and/or if a variant-specific vaccine is needed.
If you vaccinate: 	<ul style="list-style-type: none"> Separate the 2nd booster dose from the previous dose by at least 3 months. Only Moderna or Pfizer-BioNTech COVID-19 vaccine products can be administered for the 2nd booster dose. Age indications and dosage (amount injected) vary by product. Pfizer-BioNTech COVID-19 vaccine: Can be administered to people age 12 years and older. The correct dosage is 0.3 mL. Moderna COVID-19 vaccine can be administered to people age 18 years and older. The correct dosage is 0.25 mL.

CDC References and Resources:

COVID-19 by County www.cdc.gov/coronavirus/2019-ncov/your-health/covid-by-county.html
 Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States: www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html
 Interim COVID-19 Immunization Schedule for Ages 5 Years and Older: www.cdc.gov/vaccines/covid-19/downloads/COVID-19-immunization-schedule-ages-5yrs-older.pdf
 People with Certain Medical Conditions: www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-with-medical-conditions.html
 U.S. COVID-19 Vaccine Product Information: www.cdc.gov/vaccines/covid-19/info-by-product/index.html



CS331034-A 04/18/2022



Thinking About Getting a Second COVID-19 Vaccine Booster Dose

In March 2022, CDC updated its COVID-19 vaccination guidance to say that certain groups of people *may* get second boosters. If you're in one of those groups, it's up to you whether or not to get a second booster right now, based on your own benefits and risks. Your healthcare provider can help you review your options.

Here are factors to think about as you consider a second booster.

1. Are you eligible?	<p>Right now, you're eligible for a 2nd COVID-19 booster if you're:</p> <ul style="list-style-type: none"> 50 years of age and older and received an initial booster at least 4 months ago. 12 years of age and older and moderately or severely immunocompromised and received an initial booster at least 4 months ago Received 2 doses of Janssen vaccine at least 4 months ago
2. Are you (or is someone you live with) at higher risk of COVID-19?	<p>Certain factors can raise the risk of COVID-19 disease. It may be helpful to get a second booster now if you are (or if someone you live with is):</p> <ul style="list-style-type: none"> Moderately or severely immunocompromised At higher risk for severe disease At higher risk of being exposed to COVID-19 through your job, where you live, or other factors (such as frequent travel or large gatherings) In an area where COVID-19 community levels are concerning Or if someone you live with is unvaccinated.
3. Can you wait?	<p>A second booster may be more important in fall of 2022, or if a new vaccine for a future COVID-19 variant becomes available. You may consider waiting to get a second booster if you:</p> <ul style="list-style-type: none"> Had COVID-19 within the past 3 months Feel that getting a second booster now would make you not want to get another booster in the future.
If you get a second booster:	<ul style="list-style-type: none"> Make sure it's been at least 4 months since your last COVID-19 booster. Remember that second boosters can only be Moderna or Pfizer-BioNTech (and for 12-17 year-olds, only Pfizer-BioNTech). You can self-attest if you're moderately or severely immunocompromised. This means you do not need any documentation of your immunocompromised status in order to receive COVID-19 vaccines (including boosters) wherever they're offered.

CDC References and Resources:


COVID-19 by County www.cdc.gov/coronavirus/2019-ncov/your-health/covid-by-county.html
 Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States: www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html
 Interim COVID-19 Immunization Schedule for Ages 5 Years and Older: www.cdc.gov/vaccines/covid-19/downloads/COVID-19-immunization-schedule-ages-5yrs-older.pdf
 People with Certain Medical Conditions: www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-with-medical-conditions.html
 U.S. COVID-19 Vaccine Product Information: www.cdc.gov/vaccines/covid-19/info-by-product/index.html



CS331034-A 04/18/2022

Acknowledgements

- Mary Chamberland
- Megan Freedman
- Susan Goldstein
- Jarrad Hogg
- Lauren Hughes
- Sarah Meyer
- Valerie Morelli
- Sara Oliver
- Janet Wright
- JoEllen Wolicki
- VTF ACIP WG Team



For more information, contact CDC
1-800-CDC-INFO (232-4636)
TTY: 1-888-232-6348 www.cdc.gov

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.

